Accepted for/Published in: JMIR Public Health and Surveillance
Date Submitted: Apr 20, 2025
Open Peer Review Period: Apr 21, 2025 - Jun 16, 2025
Date Accepted: Jun 11, 2025
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Evaluating the Effectiveness of an Intelligent Mobile Health Intervention for Child Unintentional Injury Prevention: Protocol for a Cluster Randomized Controlled Trial
ABSTRACT
Background:
Unintentional injury is a leading cause of childhood morbidity and mortality worldwide. In China, real-world implementation of child injury prevention efforts remains inadequate due to constrained workforce capacity and a lack of operational frameworks.
Objective:
This study aims to assess the effectiveness of a mobile health (mHealth) intervention, the Intelligent Child Unintentional-injury Reduction & Education (iCURE) project, embedded within China’s National Basic Public Health Service Program. The intervention relies on a WeChat service account for caregivers and a web-based platform for healthcare providers to deliver standardized unintentional injury prevention strategies for young children. Key features of the program include interactive Q&A, injury risk assessment with instant feedback, a tailored injury prevention knowledge disseminator, and regular reminders to caregivers.
Methods:
A double-blind, 12-month follow-up, cluster randomized controlled trial will be implemented in Changsha, Hunan Province, China. At least 5,600 caregivers of children aged 5 and below will be recruited. Randomization will be conducted at the street/town level. The control group will receive traditional safety education, while the intervention group will receive both traditional safety education and the iCURE mHealth intervention focused on unintentional injury prevention and delivered via WeChat. Data will be collected at baseline and every 3 months during the study period. The primary outcome is 12-month incidence of unintentional injuries among children, including minor injuries and as reported by caregivers. Secondary outcomes include children's injury risk level and caregiver supervision behaviors assessed using a standard questionnaire. Data analysis will be conducted using generalized linear mixed models with a Poisson link function and generalized estimating equations to assess the effectiveness of the iCURE intervention, following intention-to-treat principles. Sensitivity analyses will be conducted with per-protocol principles and excluding participants with missing primary outcomes.
Results:
As of April 2025, a total of 6,704 participants have been successfully enrolled, and baseline data were collected for all participants. Of those enrolled, 82% completed the first follow-up assessment.
Conclusions:
This trial will examine the effectiveness of an intelligent mHealth intervention for child unintentional injury prevention building on China’s National Basic Public Health Service Program. If successful, the iCURE intervention may provide a cost-effective strategy for child injury prevention in low- and middle-income countries. Clinical Trial: The protocol of iCURE trial was retrospectively registered with Chinese Clinical Trial Registry (No. ChiCTR2400092698). Date of registration: November 21, 2024. Date of first participant enrollment: August 7, 2024.
Citation
The author of this paper has made a PDF available, but requires the user to login, or create an account.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.